NAMZARIC is approved for the treatment of moderate to severe Alzheimer’s
disease in patients who are currently taking and can continue to take certain
doses of both NAMENDA® (memantine HCI) or NAMENDA XR® (memantine
HCl) extended release and donepezil HCI, the active ingredient in Aricept®.
NAMZARIC is available by prescription only. NAMZARIC should not be taken by
anyone who has an allergy to memantine HCl, donepezil HCl, medicines that
contain piperidines, or any of the ingredients in NAMZARIC. See below for
additional Important Safety Information.

Please see full Prescribing Information, including Patient Information.
If your loved one is currently taking
twice-a-day NAMENDA® (memantine
HCl) and Aricept® (donepezil HCl)
10 mg, ask their doctor if once-a-day
NAMZARIC may be right for them.
NAMZARIC is the FIRST AND ONLY
treatment for moderate to severe Alzheimer's
disease that combines 2 medicines,
NAMENDA XR® (memantine HCl) extended
release and donepezil HCl, in a convenient,
once-a-day capsule.
NAMZARIC is approved for the treatment of
moderate to severe Alzheimer's disease in
patients who are currently taking and can
continue to take certain doses of both
NAMENDA or NAMENDA XR and donepezil
HCl, the active ingredient in Aricept.
NAMZARIC is available by prescription only.
Learn more about NAMZARIC.
There is no evidence that NAMZARIC
prevents or slows the underlying disease
process in patients with Alzheimer’s disease.
Learn about a 30-day Trial
Offer at $0 out-of-pocket cost
.*
Prepare for the next visit to
your loved one’s doctor
.
*Restrictions apply. See Trial Offer for details.
If your loved one has difficulty swallowing pills, NAMZARIC capsules may be opened
and sprinkled on applesauce. This may make taking medicine easier for your loved one
and for you. Just make sure the full dose is taken all at once.
Important RISK Information
Who should not take NAMZARIC?
NAMZARIC should not be taken by anyone who has an allergy to memantine HCl, donepezil HCl,
medicines that contain piperidines, or any of the ingredients in NAMZARIC.
What should be discussed with the healthcare provider before taking NAMZARIC?
Before starting NAMZARIC, talk to the healthcare provider about all of the patient’s medical conditions, including:
heart problems including an irregular, slow, or fast heartbeat
asthma or lung problems
seizures
stomach ulcers
bladder, kidney, or liver problems
any surgical, dental, or other medical procedures scheduled when anesthesia
may be used
Tell the healthcare provider about all the medicines the patient is taking, including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of NAMZARIC?
NAMZARIC may cause serious side effects, including:
muscle problems in patients given anesthesia
slow heartbeat and fainting. This happens more often in people with heart
problems. Call the doctor right away if the patient faints while taking
NAMZARIC
more stomach acid. This raises the chance of ulcers and bleeding especially
when taking NAMZARIC. The risk is higher for patients who have had ulcers,
or take aspirin or other NSAIDs
nausea and vomiting
difficulty passing urine
seizures
worsening of lung problems in people with asthma or other lung disease
The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.
The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and
bruising.
These are not all the possible side effects of NAMZARIC.
Please see full Prescribing Information, including Patient Information.
PLEASE NOTE: DO NOT REPLY TO THIS EMAIL. Emails sent to this account will not be read.
We respect your privacy. See our Privacy Policy.
For additional information about NAMZARIC, call Actavis, Inc. toll-free at 1.844.626.9274.
Harborside Financial Center 
Plaza V, Suite 1900
Jersey City, NJ 07311  
NAMENDA®, NAMENDA XR®, NAMZARICTM and their designs are trademarks of Merz Pharma GmbH & Co. KGaA.
Actavis® and its design are trademarks of Actavis, Inc. or its affiliates. 
Aricept® is a trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© Actavis 2015. All rights reserved. NMZ36104    08/15
To opt-out, please select [~Optout style="color:#009692;"~]this link[~EndOptout~] or you can write to the address below. We will remove your email address from all future offers on behalf of Take 5 Media Group. We encourage our readers to look at our Privacy Policy.

[~Physical_Mailing_Address~]
Email Marketing